floatz

Company Bio

Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Gabriele Zirpoli, Matti Kesti
Pre-Seed
United States
AI, B2B, BioTech, DeepTech
To create a structural monopoly and scale to $100M+ ARR, our business model executes a three-phase "buy-side to sell-side" strategy: Phase 1 (Investor Pays): We currently sell outsourced, tech-enabled due diligence directly to life science investors and VCs. By charging for pre-clinical asset screening, we generate early revenue projected at $1M to $3M ARR. Phase 2 (Platform Subscriptions): As our ratings become a trusted standard, we will scale by selling recurring platform subscriptions to investors. This phase is projected to generate $10M to $30M in ARR. Phase 3 (Issuer Pays): Ultimately, we will flip to an "issuer-pays" model where biotech companies themselves pay us for ratings. Just like Moody's, biotechs will need our stamp of approval to raise capital, unlocking $100M+ in ARR.

floatz is the Moody's for biotech. We build the standardized rating agency and pricing infrastructure to turn life sciences into a liquid asset class. By translating complex scientific data into clear financial signals, we make the world's most valuable asset class tradeable.